Literature DB >> 18551355

Onset dynamics of type A botulinum neurotoxin-induced paralysis.

Frank J Lebeda1, Michael Adler, Keith Erickson, Yaroslav Chushak.   

Abstract

Experimental studies have demonstrated that botulinum neurotoxin serotype A (BoNT/A) causes flaccid paralysis by a multi-step mechanism. Following its binding to specific receptors at peripheral cholinergic nerve endings, BoNT/A is internalized by receptor-mediated endocytosis. Subsequently its zinc-dependent catalytic domain translocates into the neuroplasm where it cleaves a vesicle-docking protein, SNAP-25, to block neurally evoked cholinergic neurotransmission. We tested the hypothesis that mathematical models having a minimal number of reactions and reactants can simulate published data concerning the onset of paralysis of skeletal muscles induced by BoNT/A at the isolated rat neuromuscular junction (NMJ) and in other systems. Experimental data from several laboratories were simulated with two different models that were represented by sets of coupled, first-order differential equations. In this study, the 3-step sequential model developed by Simpson (J Pharmacol Exp Ther 212:16-21,1980) was used to estimate upper limits of the times during which anti-toxins and other impermeable inhibitors of BoNT/A can exert an effect. The experimentally determined binding reaction rate was verified to be consistent with published estimates for the rate constants for BoNT/A binding to and dissociating from its receptors. Because this 3-step model was not designed to reproduce temporal changes in paralysis with different toxin concentrations, a new BoNT/A species and rate (k(S)) were added at the beginning of the reaction sequence to create a 4-step scheme. This unbound initial species is transformed at a rate determined by k(S) to a free species that is capable of binding. By systematically adjusting the values of k(S), the 4-step model simulated the rapid decline in NMJ function (k(S) >or= 0.01), the less rapid onset of paralysis in mice following i.m. injections (k (S) = 0.001), and the slow onset of the therapeutic effects of BoNT/A (k(S) < 0.001) in man. This minimal modeling approach was not only verified by simulating experimental results, it helped to quantitatively define the time available for an inhibitor to have some effect (t(inhib)) and the relation between this time and the rate of paralysis onset. The 4-step model predicted that as the rate of paralysis becomes slower, the estimated upper limits of (t(inhib)) for impermeable inhibitors become longer. More generally, this modeling approach may be useful in studying the kinetics of other toxins or viruses that invade host cells by similar mechanisms, e.g., receptor-mediated endocytosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18551355      PMCID: PMC2798021          DOI: 10.1007/s10928-008-9087-3

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  31 in total

1.  Translocation of botulinum neurotoxin light chain protease through the heavy chain channel.

Authors:  Lilia K Koriazova; Mauricio Montal
Journal:  Nat Struct Biol       Date:  2003-01

2.  Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation.

Authors:  Frédéric A Meunier; Godfrey Lisk; Dorothea Sesardic; J Oliver Dolly
Journal:  Mol Cell Neurosci       Date:  2003-04       Impact factor: 4.314

3.  Next generation simulation tools: the Systems Biology Workbench and BioSPICE integration.

Authors:  Herbert M Sauro; Michael Hucka; Andrew Finney; Cameron Wellock; Hamid Bolouri; John Doyle; Hiroaki Kitano
Journal:  OMICS       Date:  2003

4.  An initial assessment of the systemic pharmacokinetics of botulinum toxin.

Authors:  Easwaran Ravichandran; Yujing Gong; Fetweh H Al Saleem; Denise M Ancharski; Suresh G Joshi; Lance L Simpson
Journal:  J Pharmacol Exp Ther       Date:  2006-06-16       Impact factor: 4.030

Review 5.  Botulinum toxin as a biological weapon: medical and public health management.

Authors:  S S Arnon; R Schechter; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; J Hauer; M Layton; S Lillibridge; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; D L Swerdlow; K Tonat
Journal:  JAMA       Date:  2001-02-28       Impact factor: 56.272

Review 6.  Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective.

Authors:  E A Johnson; M Bradshaw
Journal:  Toxicon       Date:  2001-11       Impact factor: 3.033

7.  Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis.

Authors:  C V Jurasinski; E Lieth; A N Dang Do; C L Schengrund
Journal:  Toxicon       Date:  2001-09       Impact factor: 3.033

8.  An outbreak of serious illness and death among injecting drug users in England during 2000.

Authors:  J A Jones; J E Salmon; T Djuretic; G Nichols; R C George; O N Gill
Journal:  J Med Microbiol       Date:  2002-11       Impact factor: 2.472

9.  Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.

Authors:  K Roger Aoki
Journal:  Toxicon       Date:  2002-07       Impact factor: 3.033

Review 10.  Neurotoxins affecting neuroexocytosis.

Authors:  G Schiavo; M Matteoli; C Montecucco
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

View more
  8 in total

Review 1.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

2.  Adult neuron addition to the zebra finch song motor pathway correlates with the rate and extent of recovery from botox-induced paralysis of the vocal muscles.

Authors:  Carolyn Pytte; Yi-Lo Yu; Sara Wildstein; Shanu George; John R Kirn
Journal:  J Neurosci       Date:  2011-11-23       Impact factor: 6.167

3.  Proconvulsant actions of intrahippocampal botulinum neurotoxin B in the rat.

Authors:  S Bröer; D Zolkowska; M Gernert; M A Rogawski
Journal:  Neuroscience       Date:  2013-07-29       Impact factor: 3.590

Review 4.  The zinc-dependent protease activity of the botulinum neurotoxins.

Authors:  Frank J Lebeda; Regina Z Cer; Uma Mudunuri; Robert Stephens; Bal Ram Singh; Michael Adler
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

5.  Kinetic and reaction pathway analysis in the application of botulinum toxin a for wound healing.

Authors:  Frank J Lebeda; Zygmunt F Dembek; Michael Adler
Journal:  J Toxicol       Date:  2011-11-24

6.  SERS detection of Clostridium botulinum neurotoxin serotypes A and B in buffer and serum: Towards the development of a biodefense test platform.

Authors:  China Y Lim; Jennifer H Granger; Marc D Porter
Journal:  Anal Chim Acta X       Date:  2018-12-21

7.  IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding.

Authors:  R Z Cer; U Mudunuri; R Stephens; F J Lebeda
Journal:  Nucleic Acids Res       Date:  2009-04-24       Impact factor: 16.971

8.  The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II.

Authors:  Mark S Nestor; David Arnold; Daniel Fischer
Journal:  J Cosmet Dermatol       Date:  2020-09-16       Impact factor: 2.696

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.